DexCom, Inc. (NASDAQ:DXCM) EVP Steven Robert Pacelli sold 3,597 shares of the firm’s stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $116.71, for a total transaction of $419,805.87. Following the completion of the transaction, the executive vice president now directly owns 72,570 shares in the company, valued at approximately $8,469,644.70. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Steven Robert Pacelli also recently made the following trade(s):
- On Tuesday, April 23rd, Steven Robert Pacelli sold 3,596 shares of DexCom stock. The shares were sold at an average price of $116.61, for a total transaction of $419,329.56.
- On Friday, March 22nd, Steven Robert Pacelli sold 3,596 shares of DexCom stock. The shares were sold at an average price of $140.04, for a total transaction of $503,583.84.
DexCom stock traded up $4.51 during midday trading on Friday, hitting $118.97. 697,587 shares of the stock were exchanged, compared to its average volume of 1,302,575. DexCom, Inc. has a 52 week low of $86.55 and a 52 week high of $156.16. The firm has a market capitalization of $10.81 billion, a price-to-earnings ratio of 396.57 and a beta of 0.73. The company has a debt-to-equity ratio of 1.57, a current ratio of 7.18 and a quick ratio of 6.75.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.12. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The business had revenue of $280.50 million for the quarter, compared to analyst estimates of $246.10 million. During the same quarter last year, the firm earned ($0.30) EPS. DexCom’s quarterly revenue was up 52.1% compared to the same quarter last year. As a group, analysts predict that DexCom, Inc. will post 0.77 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in DXCM. Legal & General Group Plc raised its holdings in DexCom by 42.6% during the 3rd quarter. Legal & General Group Plc now owns 60,492 shares of the medical device company’s stock worth $8,653,000 after buying an additional 18,075 shares during the period. Vanguard Group Inc raised its holdings in shares of DexCom by 11.5% in the third quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock valued at $1,136,147,000 after purchasing an additional 816,247 shares during the last quarter. First Hawaiian Bank raised its holdings in shares of DexCom by 75.6% in the fourth quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock valued at $47,000 after purchasing an additional 170 shares during the last quarter. Meeder Asset Management Inc. raised its holdings in shares of DexCom by 2,167.0% in the fourth quarter. Meeder Asset Management Inc. now owns 2,267 shares of the medical device company’s stock valued at $272,000 after purchasing an additional 2,167 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of DexCom by 11.7% in the fourth quarter. Bank of Montreal Can now owns 66,527 shares of the medical device company’s stock valued at $7,970,000 after purchasing an additional 6,978 shares during the last quarter.
Several brokerages have recently issued reports on DXCM. Zacks Investment Research raised shares of DexCom from a “hold” rating to a “buy” rating and set a $138.00 target price on the stock in a research note on Monday, May 6th. BMO Capital Markets raised their target price on shares of DexCom from $167.00 to $172.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Raymond James reduced their target price on shares of DexCom from $160.00 to $150.00 and set an “outperform” rating on the stock in a research note on Thursday, May 2nd. Piper Jaffray Companies raised their target price on shares of DexCom to $173.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Finally, UBS Group reduced their target price on shares of DexCom from $150.00 to $140.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 30th. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $152.25.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thestockobserver.com/2019/05/24/dexcom-inc-dxcm-evp-sells-419805-87-in-stock.html.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Further Reading: Roth IRA
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.